Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Recruiting
• CT.gov ID: NCT03914612
• Collaborator: Canadian Cancer Trials Group (Other), NRG Oncology (Other)
• Enrollment: 810
• Locations: 377
• Arms: 2
• Anticipated Duration (Months): 47.5
• Patients Per Site: 2.1
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

Condition or Disease	Intervention/Treatment	Phase
Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Stage III Uterine Corpus Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8	Drug: Carboplatin; Drug: Paclitaxel; Biological: Pembrolizumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	Phase 3

Detailed Description

PRIMARY OBJECTIVE:

1. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.

SECONDARY OBJECTIVES:

1. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.

2. To evaluate blinded independent central review (BICR) assessed or investigator assessed objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by treatment arm and by mismatch repair (MMR) immunohistochemistry (IHC) status in patients who enter the study with measurable disease.

3. To evaluate BICR assessed or investigator assessed duration of response (DOR) by treatment arm and by MMR IHC status in patients who enter the study with measurable disease.

4. To evaluate the effect of pembrolizumab (MK-3475) on overall survival (OS) in patients with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR).

5. To determine whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with improved patient reported physical function as measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function scale (short form), quality of life as measured with the Functional Assessment of Cancer Therapy (FACT) - Endometrial Trial Outcome Index (En TOI) and worsened fatigue as measured with the PROMIS-Fatigue scale (short form) in the pMMR patients.

6. To determine concordance between institutional MMR immunohistochemistry (IHC) testing and centralized MMR IHC.

EXPLORATORY OBJECTIVES:

1. To explore the correlation between patient-reported physical function as measured with the PROMIS-physical function scale (short form) and quality of life as measure with the FACT-En TOI.

2. To explore whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with self-reported neurotoxicity as measured with the FACT/Gynecologic Oncology Group Neurotoxicity (GOG-Ntx) subscale (short) and the extent to which patients differ on their self-reported bother from side effects of cancer therapy in the pMMR patients.

3. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer by Programmed Death Ligand 1 (PD-L1) IHC (positive versus [vs] negative).

4. To assess the association between PD-L1 IHC (positive vs negative) and mismatch repair status (pMMR and dMMR).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I:

COMBINATION PHASE: Patients receive placebo intravenously (IV) over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease may continue treatment for up to a total 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.

MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.

ARM II:

COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.

MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 810 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
• Actual Study Start Date: Jul 16, 2019
• Anticipated Primary Completion Date: Jun 30, 2023
• Anticipated Study Completion Date: Jun 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Arm I (placebo, paclitaxel, carboplatin) COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.	Drug: Carboplatin; Given IV; Other Names: Blastocarb Carboplat Carboplatin Hexal Carboplatino Carboplatinum Carbosin Carbosol Carbotec CBDCA Displata Ercar JM-8 Nealorin Novoplatinum Paraplatin Paraplatin AQ Paraplatine Platinwas Ribocarbo ; Drug: Paclitaxel; Given IV; Other Names: Anzatax Asotax Bristaxol Praxel Taxol Taxol Konzentrat ; Other: Placebo Administration; Given IV; Other: Quality-of-Life Assessment; Ancillary studies; Other Names: Quality of Life Assessment ; Other: Questionnaire Administration; Ancillary studies
Experimental: Arm II (pembrolizumab, paclitaxel, carboplatin) COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.	Drug: Carboplatin; Given IV; Other Names: Blastocarb Carboplat Carboplatin Hexal Carboplatino Carboplatinum Carbosin Carbosol Carbotec CBDCA Displata Ercar JM-8 Nealorin Novoplatinum Paraplatin Paraplatin AQ Paraplatine Platinwas Ribocarbo ; Drug: Paclitaxel; Given IV; Other Names: Anzatax Asotax Bristaxol Praxel Taxol Taxol Konzentrat ; Biological: Pembrolizumab; Given IV; Other Names: Keytruda Lambrolizumab MK-3475 SCH 900475 ; Other: Quality-of-Life Assessment; Ancillary studies; Other Names: Quality of Life Assessment ; Other: Questionnaire Administration; Ancillary studies

Outcome Measures

Primary Outcome Measures

1. Progression-free survival (PFS) [Duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years]

   Will be tested with a stratified log-rank statistic.

Secondary Outcome Measures

1. Incidence of adverse events [5 years]

   Assessed by Common Terminology Criteria for Adverse Events (CTCAE). Toxicities will be screened for differences between treatments by using an exact method or a Chi-Square test. For a given adverse event, each patient will be graded according to the worse grade experienced while on therapy (and within 30 days of treatment). These toxicities will then be divided into two or three categories such as mild, moderate, and severe or mild to moderate versus severe. The rates of severe toxicities may be characterized by risk ratios or odds ratios with confidence intervals (unadjusted for multiplicity). The number of toxicities examined is usually fairly large, so these analyses will be considered exploratory and may be inspected in light of other studies.

2. Objective tumor response [5 years]

   Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1.

3. Duration of objective response [5 years]

   The time difference between the dates of first response and first progression; patients who do not progress are considered censored.

4. Overall survival (OS) [Time from study entry to time of death or the date of last contact, assessed up to 5 years]

5. Quality of life (QoL) and patient-reported outcomes (PROs) [5 years]

   Measured by the Function Assessment of Cancer Therapy (FACT)-Endometrial Trial Outcome Index (En-TOI), the FACT/Gynecologic Oncology Group (GOG)-Neurotoxicity (Ntx) subscale (short), Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue (short form),the PROMIS-physical function (short form) and a single-item measuring bother from side effects of cancer therapy. A linear mixed model for repeated measures will be used to estimate and compare the mean differences between the treatment groups. Model covariates will include the patients' randomly assigned study treatment, age at enrollment onto the study, pre-treatment quality of life/patient reported outcome score, assessment time and treatment-by-time interaction. The stratification factors will be the same factors included in the clinical primary analysis. Hochberg's step-up multiple testing procedure (Hochberg, 1988) will be used to adjust p-values for each assessment time points estimated from the fitted model.

6. Incidence of pembrolizumab treatment and self-reported neurotoxicity [5 years]

   Assessed with FACT/GOG-Ntx.

7. Concordance between Institutional Mismatch repair (MMR) immunohistochemistry (IHC) testing and centralized MMR IHC [5 years]

   Concordance between institutional MMR IHC testing and centralized MMR IHC. The patient's MMR IHC status will be assessed for prognostic value by conducting stratified log-rank tests or Cox Proportional Hazards (PH) modeling when assessing the impact on PFS or OS. When assessing the impact on the probability of response, a logistic regression model will be considered and include other pertinent variables that may influence response. A Cox PH model will be used to assess predictive value of MMR IHC status for regimen efficacy through an interaction term. A similar type of analysis may be attempted with response using logistic regression. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient).

8. Effect of pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC [5 years]

   Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score [CPS]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided.

9. Association between PD-L1 IHC and MMR status [5 years]

   Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.

• Pathology report showing results of institutional MMR IHC testing.

• Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).

• Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.

• In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.

• Patients may have received

• NO prior chemotherapy for treatment of endometrial cancer OR

• Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.

• Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.

• Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.

• Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.

• Age >= 18

• Performance status of 0, 1 or 2.

• Platelets >= 100,000/mcl.

• Absolute neutrophil count (ANC) >= 1,500/mcl.

• Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).

• Total serum bilirubin level =< 1.5 x upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.

• Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.

• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.

• For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.

• Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:

• Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR

• Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR

• Have a congenital or acquired condition that prevents childbearing.

• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

• The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.

Exclusion Criteria:

• Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.

• Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin

• Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.

• Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.

• Patients who have received steroids as CT scan contrast premedication may be enrolled.

• The use of inhaled or topical corticosteroids is allowed.

• The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

• The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.

• Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.

• Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.

• Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.

• Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.

• Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.

• Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.

• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

• Pregnant or lactating patients.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama at Birmingham Cancer Center	Birmingham	Alabama	United States	35233
2	Alaska Women's Cancer Care	Anchorage	Alaska	United States	99508
3	CTCA at Western Regional Medical Center	Goodyear	Arizona	United States	85338
4	NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro	Arkansas	United States	72401
5	University of Arkansas for Medical Sciences	Little Rock	Arkansas	United States	72205
6	Kaiser Permanente-Baldwin Park	Baldwin Park	California	United States	91706
7	Kaiser Permanente-Bellflower	Bellflower	California	United States	90706
8	Alta Bates Summit Medical Center-Herrick Campus	Berkeley	California	United States	94704
9	Community Cancer Institute	Clovis	California	United States	93611
10	City of Hope Comprehensive Cancer Center	Duarte	California	United States	91010
11	Kaiser Permanente - Harbor City	Harbor City	California	United States	90710
12	Kaiser Permanente-Irvine	Irvine	California	United States	92618
13	UC San Diego Moores Cancer Center	La Jolla	California	United States	92093
14	City of Hope Antelope Valley	Lancaster	California	United States	93534
15	Kaiser Permanente Los Angeles Medical Center	Los Angeles	California	United States	90027
16	Los Angeles County-USC Medical Center	Los Angeles	California	United States	90033
17	USC / Norris Comprehensive Cancer Center	Los Angeles	California	United States	90033
18	Cedars Sinai Medical Center	Los Angeles	California	United States	90048
19	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles	California	United States	90095
20	Palo Alto Medical Foundation-Gynecologic Oncology	Mountain View	California	United States	94040
21	Kaiser Permanente-Oakland	Oakland	California	United States	94611
22	Saint Joseph Hospital - Orange	Orange	California	United States	92868
23	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange	California	United States	92868
24	Eisenhower Medical Center	Rancho Mirage	California	United States	92270
25	Mercy Regional Cancer Center	Redding	California	United States	96001
26	Mercy Oncology Center	Redding	California	United States	96002
27	Kaiser Permanente-Riverside	Riverside	California	United States	92505
28	Kaiser Permanente-Roseville	Roseville	California	United States	95661
29	Kaiser Permanente Downtown Commons	Sacramento	California	United States	95814
30	Mercy Cancer Center - Sacramento	Sacramento	California	United States	95816
31	Kaiser Permanente-San Diego Zion	San Diego	California	United States	92120
32	Naval Medical Center -San Diego	San Diego	California	United States	92134
33	Zuckerberg San Francisco General Hospital	San Francisco	California	United States	94110
34	California Pacific Medical Center-Pacific Campus	San Francisco	California	United States	94115
35	Kaiser Permanente-San Francisco	San Francisco	California	United States	94115
36	UCSF Medical Center-Mission Bay	San Francisco	California	United States	94158
37	Kaiser Permanente-Santa Teresa-San Jose	San Jose	California	United States	95119
38	Kaiser Permanente San Leandro	San Leandro	California	United States	94577
39	Kaiser Permanente-San Marcos	San Marcos	California	United States	92078
40	Kaiser Permanente Medical Center - Santa Clara	Santa Clara	California	United States	95051
41	City of Hope South Pasadena	South Pasadena	California	United States	91030
42	Kaiser Permanente-South San Francisco	South San Francisco	California	United States	94080
43	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale	California	United States	94086
44	City of Hope Upland	Upland	California	United States	91786
45	Kaiser Permanente-Vallejo	Vallejo	California	United States	94589
46	Kaiser Permanente-Walnut Creek	Walnut Creek	California	United States	94596
47	John Muir Medical Center-Walnut Creek	Walnut Creek	California	United States	94598
48	Penrose-Saint Francis Healthcare	Colorado Springs	Colorado	United States	80907
49	UCHealth Memorial Hospital Central	Colorado Springs	Colorado	United States	80909
50	Memorial Hospital North	Colorado Springs	Colorado	United States	80920
51	Poudre Valley Hospital	Fort Collins	Colorado	United States	80524
52	Cancer Care and Hematology-Fort Collins	Fort Collins	Colorado	United States	80528
53	North Colorado Medical Center	Greeley	Colorado	United States	80631
54	UCHealth Greeley Hospital	Greeley	Colorado	United States	80631
55	Medical Center of the Rockies	Loveland	Colorado	United States	80538
56	McKee Medical Center	Loveland	Colorado	United States	80539
57	Danbury Hospital	Danbury	Connecticut	United States	06810
58	Smilow Cancer Hospital Care Center - Guiford	Guilford	Connecticut	United States	06437
59	Hartford Hospital	Hartford	Connecticut	United States	06102
60	Smilow Cancer Hospital Care Center at Saint Francis	Hartford	Connecticut	United States	06105
61	The Hospital of Central Connecticut	New Britain	Connecticut	United States	06050
62	Yale University	New Haven	Connecticut	United States	06520
63	Yale-New Haven Hospital North Haven Medical Center	North Haven	Connecticut	United States	06473
64	Norwalk Hospital	Norwalk	Connecticut	United States	06856
65	Stamford Hospital/Bennett Cancer Center	Stamford	Connecticut	United States	06904
66	Smilow Cancer Hospital-Torrington Care Center	Torrington	Connecticut	United States	06790
67	Smilow Cancer Hospital Care Center-Trumbull	Trumbull	Connecticut	United States	06611
68	Smilow Cancer Hospital-Waterbury Care Center	Waterbury	Connecticut	United States	06708
69	Smilow Cancer Hospital Care Center - Waterford	Waterford	Connecticut	United States	06385
70	Helen F Graham Cancer Center	Newark	Delaware	United States	19713
71	MedStar Washington Hospital Center	Washington	District of Columbia	United States	20010
72	Sibley Memorial Hospital	Washington	District of Columbia	United States	20016
73	Florida Cancer Specialists - Bradenton	Bradenton	Florida	United States	34209
74	Florida Cancer Specialists - Sarasota	Sarasota	Florida	United States	34232
75	Florida Cancer Specialists - Sarasota Downtown	Sarasota	Florida	United States	34236
76	Sarasota Memorial Hospital	Sarasota	Florida	United States	34239
77	Florida Cancer Specialists - Venice Island	Venice	Florida	United States	34285
78	Florida Cancer Specialists - Venice Healthpark	Venice	Florida	United States	34292
79	Grady Health System	Atlanta	Georgia	United States	30303
80	Emory University Hospital Midtown	Atlanta	Georgia	United States	30308
81	Emory University Hospital/Winship Cancer Institute	Atlanta	Georgia	United States	30322
82	Emory Saint Joseph's Hospital	Atlanta	Georgia	United States	30342
83	Northside Hospital	Atlanta	Georgia	United States	30342
84	WellStar Cobb Hospital	Austell	Georgia	United States	30106
85	Piedmont Fayette Hospital	Fayetteville	Georgia	United States	30214
86	Northeast Georgia Medical Center-Gainesville	Gainesville	Georgia	United States	30501
87	WellStar Health System Inc	Marietta	Georgia	United States	30060
88	Wellstar Kennestone Hospital	Marietta	Georgia	United States	30060
89	CTCA at Southeastern Regional Medical Center	Newnan	Georgia	United States	30265
90	WellStar North Fulton Hospital	Roswell	Georgia	United States	30076
91	Memorial Health University Medical Center	Savannah	Georgia	United States	31404
92	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah	Georgia	United States	31405
93	WellStar Vinings Health Park	Smyrna	Georgia	United States	30080
94	Queen's Medical Center	Honolulu	Hawaii	United States	96813
95	Kapiolani Medical Center for Women and Children	Honolulu	Hawaii	United States	96826
96	Saint Alphonsus Cancer Care Center-Boise	Boise	Idaho	United States	83706
97	Saint Luke's Cancer Institute - Boise	Boise	Idaho	United States	83712
98	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell	Idaho	United States	83605
99	Saint Luke's Cancer Institute - Fruitland	Fruitland	Idaho	United States	83619
100	Saint Luke's Cancer Institute - Meridian	Meridian	Idaho	United States	83642
101	Saint Alphonsus Medical Center-Nampa	Nampa	Idaho	United States	83686
102	Saint Luke's Cancer Institute - Nampa	Nampa	Idaho	United States	83686
103	Saint Luke's Cancer Institute - Twin Falls	Twin Falls	Idaho	United States	83301
104	Northwestern University	Chicago	Illinois	United States	60611
105	Rush University Medical Center	Chicago	Illinois	United States	60612
106	University of Illinois	Chicago	Illinois	United States	60612
107	University of Chicago Comprehensive Cancer Center	Chicago	Illinois	United States	60637
108	Carle on Vermilion	Danville	Illinois	United States	61832
109	Cancer Care Specialists of Illinois - Decatur	Decatur	Illinois	United States	62526
110	Crossroads Cancer Center	Effingham	Illinois	United States	62401
111	NorthShore University HealthSystem-Evanston Hospital	Evanston	Illinois	United States	60201
112	Northwestern Medicine Cancer Center Delnor	Geneva	Illinois	United States	60134
113	NorthShore University HealthSystem-Glenbrook Hospital	Glenview	Illinois	United States	60026
114	Ingalls Memorial Hospital	Harvey	Illinois	United States	60426
115	NorthShore University HealthSystem-Highland Park Hospital	Highland Park	Illinois	United States	60035
116	Carle Physician Group-Mattoon/Charleston	Mattoon	Illinois	United States	61938
117	Loyola University Medical Center	Maywood	Illinois	United States	60153
118	UC Comprehensive Cancer Center at Silver Cross	New Lenox	Illinois	United States	60451
119	Cancer Care Center of O'Fallon	O'Fallon	Illinois	United States	62269
120	University of Chicago Medicine-Orland Park	Orland Park	Illinois	United States	60462
121	Springfield Clinic	Springfield	Illinois	United States	62702
122	Carle Cancer Center	Urbana	Illinois	United States	61801
123	Northwestern Medicine Cancer Center Warrenville	Warrenville	Illinois	United States	60555
124	Midwestern Regional Medical Center	Zion	Illinois	United States	60099
125	Northwest Cancer Center - Main Campus	Crown Point	Indiana	United States	46307
126	Northwest Oncology LLC	Dyer	Indiana	United States	46311
127	Northwest Cancer Center - Hobart	Hobart	Indiana	United States	46342
128	Saint Mary Medical Center	Hobart	Indiana	United States	46342
129	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	United States	46202
130	Community Cancer Center East	Indianapolis	Indiana	United States	46219
131	Community Cancer Center South	Indianapolis	Indiana	United States	46227
132	Franciscan Health Indianapolis	Indianapolis	Indiana	United States	46237
133	Community Cancer Center North	Indianapolis	Indiana	United States	46256
134	Saint Vincent Hospital and Health Care Center	Indianapolis	Indiana	United States	46260
135	Saint Catherine Hospital	Indianapolis	Indiana	United States	46312
136	Franciscan Health Mooresville	Mooresville	Indiana	United States	46158
137	The Community Hospital	Munster	Indiana	United States	46321
138	Women's Diagnostic Center - Munster	Munster	Indiana	United States	46321
139	Northwest Cancer Center - Valparaiso	Valparaiso	Indiana	United States	46383
140	University of Iowa/Holden Comprehensive Cancer Center	Iowa City	Iowa	United States	52242
141	University of Kansas Clinical Research Center	Fairway	Kansas	United States	66205
142	University of Kansas Cancer Center	Kansas City	Kansas	United States	66160
143	University of Kansas Hospital-Westwood Cancer Center	Westwood	Kansas	United States	66205
144	Saint Elizabeth Healthcare Edgewood	Edgewood	Kentucky	United States	41017
145	LSU Health Baton Rouge-North Clinic	Baton Rouge	Louisiana	United States	70805
146	Our Lady of the Lake Physicians Group - Medical Oncology	Baton Rouge	Louisiana	United States	70809
147	Our Lady of the Lake Medical Oncology	Baton Rouge	Louisiana	United States	70817
148	Woman's Hospital	Baton Rouge	Louisiana	United States	70817
149	East Jefferson General Hospital	Metairie	Louisiana	United States	70006
150	University Medical Center New Orleans	New Orleans	Louisiana	United States	70112
151	Ochsner Baptist Medical Center	New Orleans	Louisiana	United States	70115
152	Ochsner Medical Center Jefferson	New Orleans	Louisiana	United States	70121
153	Harold Alfond Center for Cancer Care	Augusta	Maine	United States	04330
154	Waldo County General Hospital	Belfast	Maine	United States	04915
155	MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford	Biddeford	Maine	United States	04005
156	Lafayette Family Cancer Center-EMMC	Brewer	Maine	United States	04412
157	Penobscot Bay Medical Center	Rockport	Maine	United States	04856
158	MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford	Sanford	Maine	United States	04073
159	Maine Medical Center- Scarborough Campus	Scarborough	Maine	United States	04074
160	Anne Arundel Medical Center	Annapolis	Maryland	United States	21401
161	University of Maryland/Greenebaum Cancer Center	Baltimore	Maryland	United States	21201
162	Greater Baltimore Medical Center	Baltimore	Maryland	United States	21204
163	Sinai Hospital of Baltimore	Baltimore	Maryland	United States	21215
164	Saint Agnes Hospital	Baltimore	Maryland	United States	21229
165	MedStar Franklin Square Medical Center/Weinberg Cancer Institute	Baltimore	Maryland	United States	21237
166	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	Maryland	United States	21287
167	UM Upper Chesapeake Medical Center	Bel Air	Maryland	United States	21014
168	Walter Reed National Military Medical Center	Bethesda	Maryland	United States	20889-5600
169	University of Maryland Shore Medical Center at Easton	Easton	Maryland	United States	21601
170	Lahey Hospital and Medical Center	Burlington	Massachusetts	United States	01805
171	Lowell General Hospital	Lowell	Massachusetts	United States	01854
172	Baystate Medical Center	Springfield	Massachusetts	United States	01199
173	Winchester Hospital	Winchester	Massachusetts	United States	01890
174	UMass Memorial Medical Center - Memorial Division	Worcester	Massachusetts	United States	01605
175	Saint Joseph Mercy Hospital	Ann Arbor	Michigan	United States	48106
176	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	United States	48109
177	Genesee Cancer and Blood Disease Treatment Center	Flint	Michigan	United States	48503
178	Genesee Hematology Oncology PC	Flint	Michigan	United States	48503
179	Genesys Hurley Cancer Institute	Flint	Michigan	United States	48503
180	Spectrum Health at Butterworth Campus	Grand Rapids	Michigan	United States	49503
181	Bronson Methodist Hospital	Kalamazoo	Michigan	United States	49007
182	West Michigan Cancer Center	Kalamazoo	Michigan	United States	49007
183	Sparrow Hospital	Lansing	Michigan	United States	48912
184	Munson Medical Center	Traverse City	Michigan	United States	49684
185	Sanford Joe Lueken Cancer Center	Bemidji	Minnesota	United States	56601
186	Essentia Health Cancer Center	Duluth	Minnesota	United States	55805
187	Mayo Clinic in Rochester	Rochester	Minnesota	United States	55905
188	Mississippi Baptist Medical Center	Jackson	Mississippi	United States	39202
189	University of Mississippi Medical Center	Jackson	Mississippi	United States	39216
190	Saint Luke's Hospital of Kansas City	Kansas City	Missouri	United States	64111
191	Washington University School of Medicine	Saint Louis	Missouri	United States	63110
192	Mercy Hospital Saint Louis	Saint Louis	Missouri	United States	63141
193	Mercy Hospital Springfield	Springfield	Missouri	United States	65804
194	Community Hospital of Anaconda	Anaconda	Montana	United States	59711
195	Billings Clinic Cancer Center	Billings	Montana	United States	59101
196	CHI Health Saint Francis	Grand Island	Nebraska	United States	68803
197	Nebraska Methodist Hospital	Omaha	Nebraska	United States	68114
198	University of Nebraska Medical Center	Omaha	Nebraska	United States	68198
199	Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey	United States	07920
200	Monmouth Medical Center Southern Campus	Lakewood	New Jersey	United States	08701
201	Saint Barnabas Medical Center	Livingston	New Jersey	United States	07039
202	Monmouth Medical Center	Long Branch	New Jersey	United States	07740
203	Memorial Sloan Kettering Monmouth	Middletown	New Jersey	United States	07748
204	Memorial Sloan Kettering Bergen	Montvale	New Jersey	United States	07645
205	Jersey Shore Medical Center	Neptune	New Jersey	United States	07753
206	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	United States	08903
207	The Valley Hospital-Luckow Pavilion	Paramus	New Jersey	United States	07652
208	Neurosurgeons of New Jersey-Ridgewood	Ridgewood	New Jersey	United States	07450
209	Valley Hospital	Ridgewood	New Jersey	United States	07450
210	Robert Wood Johnson University Hospital Somerset	Somerville	New Jersey	United States	08876
211	Community Medical Center	Toms River	New Jersey	United States	08755
212	Valley Medical Group - Wayne Multispecialty Practice	Wayne	New Jersey	United States	07470
213	Valley Health System-Hematology/Oncology	Westwood	New Jersey	United States	07675
214	University of New Mexico Cancer Center	Albuquerque	New Mexico	United States	87102
215	Southwest Gynecologic Oncology Associates Inc	Albuquerque	New Mexico	United States	87106
216	Northwell Health Imbert Cancer Center	Bay Shore	New York	United States	11706
217	Island Gynecologic Oncology	Brightwaters	New York	United States	11718
218	Montefiore Medical Center-Einstein Campus	Bronx	New York	United States	10461
219	Montefiore Medical Center - Moses Campus	Bronx	New York	United States	10467
220	New York-Presbyterian/Brooklyn Methodist Hospital	Brooklyn	New York	United States	11215
221	Roswell Park Cancer Institute	Buffalo	New York	United States	14263
222	Memorial Sloan Kettering Commack	Commack	New York	United States	11725
223	The New York Hospital Medical Center of Queens	Flushing	New York	United States	11355
224	Memorial Sloan Kettering Westchester	Harrison	New York	United States	10604
225	Northwell Health/Center for Advanced Medicine	Lake Success	New York	United States	11042
226	NYU Winthrop Hospital	Mineola	New York	United States	11501
227	Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	United States	10016
228	NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York	New York	United States	10032
229	Memorial Sloan Kettering Cancer Center	New York	New York	United States	10065
230	NYP/Weill Cornell Medical Center	New York	New York	United States	10065
231	Highland Hospital	Rochester	New York	United States	14620
232	University of Rochester	Rochester	New York	United States	14642
233	Staten Island University Hospital	Staten Island	New York	United States	10305
234	Stony Brook University Medical Center	Stony Brook	New York	United States	11794
235	State University of New York Upstate Medical University	Syracuse	New York	United States	13210
236	Memorial Sloan Kettering Nassau	Uniondale	New York	United States	11553
237	UNC Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina	United States	27599
238	Carolinas Medical Center/Levine Cancer Institute	Charlotte	North Carolina	United States	28203
239	Southeastern Medical Oncology Center-Clinton	Clinton	North Carolina	United States	28328
240	Atrium Health Cabarrus/LCI-Concord	Concord	North Carolina	United States	28025
241	Southeastern Medical Oncology Center-Goldsboro	Goldsboro	North Carolina	United States	27534
242	Margaret R Pardee Memorial Hospital	Hendersonville	North Carolina	United States	28791
243	Southeastern Medical Oncology Center-Jacksonville	Jacksonville	North Carolina	United States	28546
244	New Hanover Regional Medical Center/Zimmer Cancer Center	Wilmington	North Carolina	United States	28401
245	Wake Forest University Health Sciences	Winston-Salem	North Carolina	United States	27157
246	Sanford Bismarck Medical Center	Bismarck	North Dakota	United States	58501
247	Sanford Broadway Medical Center	Fargo	North Dakota	United States	58122
248	Sanford Roger Maris Cancer Center	Fargo	North Dakota	United States	58122
249	Summa Health System - Akron Campus	Akron	Ohio	United States	44304
250	UHHS-Chagrin Highlands Medical Center	Beachwood	Ohio	United States	44122
251	Aultman Health Foundation	Canton	Ohio	United States	44710
252	Geauga Hospital	Chardon	Ohio	United States	44024
253	University of Cincinnati Cancer Center-UC Medical Center	Cincinnati	Ohio	United States	45219
254	Good Samaritan Hospital - Cincinnati	Cincinnati	Ohio	United States	45220
255	Case Western Reserve University	Cleveland	Ohio	United States	44106
256	MetroHealth Medical Center	Cleveland	Ohio	United States	44109
257	Cleveland Clinic Cancer Center/Fairview Hospital	Cleveland	Ohio	United States	44111
258	Cleveland Clinic Foundation	Cleveland	Ohio	United States	44195
259	Ohio State University Comprehensive Cancer Center	Columbus	Ohio	United States	43210
260	Riverside Methodist Hospital	Columbus	Ohio	United States	43214
261	The Mark H Zangmeister Center	Columbus	Ohio	United States	43219
262	Hillcrest Hospital Cancer Center	Mayfield Heights	Ohio	United States	44124
263	UH Seidman Cancer Center at Lake Health Mentor Campus	Mentor	Ohio	United States	44060
264	ProMedica Flower Hospital	Sylvania	Ohio	United States	43560
265	University of Cincinnati Cancer Center-West Chester	West Chester	Ohio	United States	45069
266	UH Seidman Cancer Center at Saint John Medical Center	Westlake	Ohio	United States	44145
267	University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma	United States	73104
268	Oklahoma Cancer Specialists and Research Institute-Tulsa	Tulsa	Oklahoma	United States	74146
269	Saint Charles Health System	Bend	Oregon	United States	97701
270	Saint Alphonsus Medical Center-Ontario	Ontario	Oregon	United States	97914
271	Legacy Good Samaritan Hospital and Medical Center	Portland	Oregon	United States	97210
272	Providence Portland Medical Center	Portland	Oregon	United States	97213
273	Providence Saint Vincent Medical Center	Portland	Oregon	United States	97225
274	Legacy Meridian Park Hospital	Tualatin	Oregon	United States	97062
275	Lehigh Valley Hospital-Cedar Crest	Allentown	Pennsylvania	United States	18103
276	Lehigh Valley Hospital - Muhlenberg	Bethlehem	Pennsylvania	United States	18017
277	Geisinger Medical Center	Danville	Pennsylvania	United States	17822
278	Ephrata Cancer Center	Ephrata	Pennsylvania	United States	17522
279	Adams Cancer Center	Gettysburg	Pennsylvania	United States	17325
280	Cherry Tree Cancer Center	Hanover	Pennsylvania	United States	17331
281	Jefferson Hospital	Jefferson Hills	Pennsylvania	United States	15025
282	Lancaster General Ann B Barshinger Cancer Institute	Lancaster	Pennsylvania	United States	17601
283	Lancaster General Hospital	Lancaster	Pennsylvania	United States	17602
284	Sechler Family Cancer Center	Lebanon	Pennsylvania	United States	17042
285	Forbes Hospital	Monroeville	Pennsylvania	United States	15146
286	UPMC Hillman Cancer Center - Monroeville	Monroeville	Pennsylvania	United States	15146
287	Thomas Jefferson University Hospital	Philadelphia	Pennsylvania	United States	19107
288	UPMC-Magee Womens Hospital	Pittsburgh	Pennsylvania	United States	15213
289	West Penn Hospital	Pittsburgh	Pennsylvania	United States	15224
290	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	United States	15232
291	Geisinger Cancer Services-Pottsville	Pottsville	Pennsylvania	United States	17901
292	Reading Hospital	West Reading	Pennsylvania	United States	19611
293	Wexford Health and Wellness Pavilion	Wexford	Pennsylvania	United States	15090
294	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre	Pennsylvania	United States	18711
295	Asplundh Cancer Pavilion	Willow Grove	Pennsylvania	United States	19090
296	WellSpan Health-York Cancer Center	York	Pennsylvania	United States	17403
297	WellSpan Health-York Hospital	York	Pennsylvania	United States	17403
298	Women and Infants Hospital	Providence	Rhode Island	United States	02905
299	Medical University of South Carolina	Charleston	South Carolina	United States	29425
300	Saint Francis Hospital	Greenville	South Carolina	United States	29601
301	Prisma Health Cancer Institute - Faris	Greenville	South Carolina	United States	29605
302	Saint Francis Cancer Center	Greenville	South Carolina	United States	29607
303	Prisma Health Cancer Institute - Seneca	Seneca	South Carolina	United States	29672
304	Rapid City Regional Hospital	Rapid City	South Dakota	United States	57701
305	Sanford Cancer Center Oncology Clinic	Sioux Falls	South Dakota	United States	57104
306	Avera Cancer Institute	Sioux Falls	South Dakota	United States	57105
307	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis	Tennessee	United States	38120
308	Vanderbilt University/Ingram Cancer Center	Nashville	Tennessee	United States	37232
309	Parkland Memorial Hospital	Dallas	Texas	United States	75235
310	UT Southwestern/Simmons Cancer Center-Dallas	Dallas	Texas	United States	75390
311	Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston	Texas	United States	77030
312	Ben Taub General Hospital	Houston	Texas	United States	77030
313	Houston Methodist Hospital	Houston	Texas	United States	77030
314	Methodist Willowbrook Hospital	Houston	Texas	United States	77070
315	Houston Methodist Sugar Land Hospital	Sugar Land	Texas	United States	77479
316	Houston Methodist The Woodlands Hospital	The Woodlands	Texas	United States	77385
317	University of Utah Sugarhouse Health Center	Salt Lake City	Utah	United States	84106
318	Huntsman Cancer Institute/University of Utah	Salt Lake City	Utah	United States	84112
319	University of Vermont Medical Center	Burlington	Vermont	United States	05401
320	University of Virginia Cancer Center	Charlottesville	Virginia	United States	22908
321	Virginia Commonwealth University/Massey Cancer Center	Richmond	Virginia	United States	23298
322	MultiCare Gig Harbor Medical Park	Gig Harbor	Washington	United States	98335
323	Kadlec Clinic Hematology and Oncology	Kennewick	Washington	United States	99336
324	MultiCare Good Samaritan Hospital	Puyallup	Washington	United States	98372
325	Valley Medical Center	Renton	Washington	United States	98055
326	Swedish Medical Center-First Hill	Seattle	Washington	United States	98122-4307
327	MultiCare Tacoma General Hospital	Tacoma	Washington	United States	98405
328	Legacy Salmon Creek Hospital	Vancouver	Washington	United States	98686
329	West Virginia University Charleston Division	Charleston	West Virginia	United States	25304
330	Monongalia Hospital	Morgantown	West Virginia	United States	26505
331	West Virginia University Healthcare	Morgantown	West Virginia	United States	26506
332	Aurora Cancer Care-Southern Lakes VLCC	Burlington	Wisconsin	United States	53105
333	Marshfield Medical Center-EC Cancer Center	Eau Claire	Wisconsin	United States	54701
334	Aurora Health Care Germantown Health Center	Germantown	Wisconsin	United States	53022
335	Aurora Cancer Care-Grafton	Grafton	Wisconsin	United States	53024
336	Aurora BayCare Medical Center	Green Bay	Wisconsin	United States	54311
337	Aurora Cancer Care-Kenosha South	Kenosha	Wisconsin	United States	53142
338	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin	United States	53792
339	Aurora Bay Area Medical Group-Marinette	Marinette	Wisconsin	United States	54143
340	Marshfield Medical Center-Marshfield	Marshfield	Wisconsin	United States	54449
341	Aurora Cancer Care-Milwaukee	Milwaukee	Wisconsin	United States	53209
342	Aurora Saint Luke's Medical Center	Milwaukee	Wisconsin	United States	53215
343	Aurora Sinai Medical Center	Milwaukee	Wisconsin	United States	53233
344	Marshfield Clinic-Minocqua Center	Minocqua	Wisconsin	United States	54548
345	ProHealth Oconomowoc Memorial Hospital	Oconomowoc	Wisconsin	United States	53066
346	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh	Wisconsin	United States	54904
347	Aurora Cancer Care-Racine	Racine	Wisconsin	United States	53406
348	Marshfield Medical Center-Rice Lake	Rice Lake	Wisconsin	United States	54868
349	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan	Wisconsin	United States	53081
350	Marshfield Medical Center-River Region at Stevens Point	Stevens Point	Wisconsin	United States	54482
351	Aurora Medical Center in Summit	Summit	Wisconsin	United States	53066
352	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers	Wisconsin	United States	54241
353	UW Cancer Center at ProHealth Care	Waukesha	Wisconsin	United States	53188
354	Aurora Cancer Care-Milwaukee West	Wauwatosa	Wisconsin	United States	53226
355	Aurora West Allis Medical Center	West Allis	Wisconsin	United States	53227
356	Marshfield Medical Center - Weston	Weston	Wisconsin	United States	54476
357	The Moncton Hospital	Moncton	New Brunswick	Canada	E1C 6Z8
358	Royal Victoria Regional Health Centre	Barrie	Ontario	Canada	L4M 6M2
359	Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Ontario	Canada	L8V 5C2
360	Kingston Health Sciences Centre	Kingston	Ontario	Canada	K7L 2V7
361	London Regional Cancer Program	London	Ontario	Canada	N6A 4L6
362	Lakeridge Health Oshawa	Oshawa	Ontario	Canada	L1G 2B9
363	Algoma District Cancer Program Sault Area Hospital	Sault Ste Marie	Ontario	Canada	P6B 0A8
364	Health Sciences North	Sudbury	Ontario	Canada	P3E 5J1
365	Odette Cancer Centre- Sunnybrook Health Sciences Centre	Toronto	Ontario	Canada	M4N 3M5
366	University Health Network-Princess Margaret Hospital	Toronto	Ontario	Canada	M5G 2M9
367	Hopital de la Cite-de-la-Sante	Laval	Quebec	Canada	H7M 3L9
368	CHUM - Centre Hospitalier de l'Universite de Montreal	Montreal	Quebec	Canada	H2X 3E4
369	Allan Blair Cancer Centre	Regina	Saskatchewan	Canada	S4T 7T1
370	Ehime University Hospital	Toon	Ehime	Japan	791-0295
371	Kure National Hospital	Kure	Hiroshima	Japan	737
372	Saitama Medical University International Medical Center	Saitama		Japan	350-1298
373	Keimyung University-Dongsan Medical Center	Dalseo-gu	Daegu	Korea, Republic of	42601
374	Samsung Changwon Hospital	Seoul	Gyeongsangnam-do	Korea, Republic of	51353
375	Gangnam Severance Hospital	Seoul		Korea, Republic of	06273
376	Korea Cancer Center Hospital	Seoul		Korea, Republic of	139-706
377	Centro Comprensivo de Cancer de UPR	San Juan		Puerto Rico	00927

Sponsors and Collaborators

• National Cancer Institute (NCI)
• Canadian Cancer Trials Group
• NRG Oncology

Investigators

• Principal Investigator: Ramez N Eskander, NRG Oncology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: National Cancer Institute (NCI)
• ClinicalTrials.gov Identifier: NCT03914612
• Other Study ID Numbers: NCI-2019-02186; NCI-2019-02186; NRG-GY018; NRG-GY018; U10CA180868
• First Posted: Apr 16, 2019
• Last Update Posted: Aug 25, 2022
• Last Verified: Jun 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Carcinoma; Adenocarcinoma; Endometrial Neoplasms; Cystadenocarcinoma, Serous; Carcinoma, Endometrioid; Adenocarcinoma, Clear Cell; Recurrence; Paclitaxel; Carboplatin; Pembrolizumab; Albumin-Bound Paclitaxel

Study Results

No Results Posted as of Aug 25, 2022